491 related articles for article (PubMed ID: 24608404)
1. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
Ann Rheum Dis; 2015 Jun; 74(6):1065-71. PubMed ID: 24608404
[TBL] [Abstract][Full Text] [Related]
2. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
4. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.
Curtis JR; Yang S; Patkar NM; Chen L; Singh JA; Cannon GW; Mikuls TR; Delzell E; Saag KG; Safford MM; DuVall S; Alexander K; Napalkov P; Winthrop KL; Burton MJ; Kamauu A; Baddley JW
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):990-7. PubMed ID: 24470378
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
6. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
[TBL] [Abstract][Full Text] [Related]
7. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
[TBL] [Abstract][Full Text] [Related]
8. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
Curtis JR; Xie F; Yun H; Saag KG; Chen L; Delzell E
Arthritis Rheumatol; 2015 Jun; 67(6):1456-64. PubMed ID: 25708920
[TBL] [Abstract][Full Text] [Related]
9. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.
Curtis JR; Xie F; Chen L; Muntner P; Grijalva CG; Spettell C; Fernandes J; McMahan RM; Baddley JW; Saag KG; Beukelman T; Delzell E
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1480-9. PubMed ID: 22833479
[TBL] [Abstract][Full Text] [Related]
10. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
11. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
Neovius M; Arkema EV; Olsson H; Eriksson JK; Kristensen LE; Simard JF; Askling J;
Ann Rheum Dis; 2015 Feb; 74(2):354-60. PubMed ID: 24285495
[TBL] [Abstract][Full Text] [Related]
12. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
[TBL] [Abstract][Full Text] [Related]
13. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
Zhang J; Xie F; Delzell E; Yun H; Lewis JD; Haynes K; Chen L; Beukelman T; Saag KG; Curtis JR
Arthritis Care Res (Hoboken); 2015 May; 67(5):624-32. PubMed ID: 25370912
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
Zhang J; Xie F; Yun H; Chen L; Muntner P; Levitan EB; Safford MM; Kent ST; Osterman MT; Lewis JD; Saag K; Singh JA; Curtis JR
Ann Rheum Dis; 2016 Oct; 75(10):1813-8. PubMed ID: 26792814
[TBL] [Abstract][Full Text] [Related]
16. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
17. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
[TBL] [Abstract][Full Text] [Related]
18. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.
Curtis JR; Xie F; Chen L; Baddley JW; Beukelman T; Saag KG; Spettell C; McMahan RM; Fernandes J; Winthrop K; Delzell E
Ann Rheum Dis; 2011 Aug; 70(8):1401-6. PubMed ID: 21586439
[TBL] [Abstract][Full Text] [Related]
19. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.
Rubbert-Roth A; Finckh A
Arthritis Res Ther; 2009; 11 Suppl 1(Suppl 1):S1. PubMed ID: 19368701
[TBL] [Abstract][Full Text] [Related]
20. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]